*ST中絨(000982.SZ)與康明百奧簽署戰略合作協議 共同推進“Mebs-lg”平台發展
格隆匯2月25日丨*ST中絨(000982.SZ)公佈,2020年2月23日,公司與北京康明百奧新藥研發有限公司(“康明百奧”)在北京市簽署了《戰略合作框架協議》,就雙方共同推進“Mebs-lg”(抗體編輯的雙特異性抗體)平台發展,並擇機在國內落地CDMO平台,為客户實現新型藥物研發提供一站式技術服務開展戰略合作。
康明百奧成立於2014年1月20日,是一家致力於創新抗體藥物研發的創新驅動型公司。康明百奧聚焦蛋白藥物在惡性腫瘤、免疫系統疾病、傳染病、重大疫情等對抗體藥物和技術的需求,研製自主知識產權的創新型單克隆抗體藥物和生物類似藥;利用全人源及人源化單克隆抗體篩選平台、哺乳動物細胞培養中試生產平台、蛋白藥物的高效表達製備等平台開展抗體新藥的篩選、研究。
對公司而言,醫療健康行業是全新的領域。此次對外投資的標的公司是免疫治療領域的優秀企業,具備較強的研發能力及優秀的產品體系。公司將根據國家發展規劃,及時把握投資機會,通過本次合作,充分利用合作企業在醫療健康領域行業優勢,結合上市公司優勢進一步實現資源優化整合,有望開拓新的增長點,提升整體盈利能力,更好的為上市公司快速發展創造機會。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.